+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets



The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets



Molecular Cell 39(1): 8-24



The abundant nuclear enzyme PARP-1, a multifunctional regulator of chromatin structure, transcription, and genomic integrity, plays key roles in a wide variety of processes in the nucleus. Recent studies have begun to connect the molecular functions of PARP-1 to specific physiological and pathological outcomes, many of which can be altered by an expanding array of chemical inhibitors of PARP enzymatic activity.

(PDF emailed within 0-6 h: $19.90)

Accession: 056206111

Download citation: RISBibTeXText

PMID: 20603072

DOI: 10.1016/j.molcel.2010.06.017


Related references

Glucocorticoid actions on airway epithelial responses in immunity: functional outcomes and molecular targets. Journal of Allergy and Clinical Immunology 120(6): 1247-63; Quiz 1264-5, 2007

Why side-effect outcomes do not affect intuitions about intentional actions: properly shifting the focus from intentional outcomes back to intentional actions. Journal of Personality and Social Psychology 108(1): 18-36, 2015

Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation. Science 353(6294): 45-50, 2016

Molecular and physiological actions of quercetin: need for clinical trials to assess its benefits in human disease. Nutrition Reviews 72(11): 720-734, 2015

Molecular targets against mustard toxicity: implication of cell surface receptors, peroxynitrite production, and PARP activation. Archives of Toxicology 80(10): 662-670, 2006

Physiological role for cleavage of PARP during cell death Lesson from expression of caspase-3-uncleavable PARP. FASEB Journal 13(7): A1343, April 23, 1999

PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Research 36(13): 4454-4464, 2008

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell Chemical Biology (): -, 2016

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmacogenomics and Personalized Medicine 7: 203-215, 2014

Molecular cloning of PARP from human cartilage and subsequent demonstration that PARP is a fragment of the amino domain of the collagen alpha-2 chain. FEBS (Federation of European Biochemical Societies) Letters 326(1-3): 25-28, 1993

Boswellic acids: biological actions and molecular targets. Current Medicinal Chemistry 13(28): 3359-3369, 2006

Physiological identification of the targets of cartwheel cells in the dorsal cochlear nucleus. Journal of Neurophysiology 78(1): 248-260, 1997

Actions of adrenomedullin in the paraventricular nucleus Physiological consequences and cellular correlates. Society for Neuroscience Abstracts 25(1-2): 1956, 1999

Signal transduction pathways. Molecular targets for lithium's actions. Archives of General Psychiatry 52(7): 531-543, 1995